Our research shows that those at high genetic risk of obesity will need personalised support to help them stay at, or return to, a healthy weight.

Genomics releases new research showing significant link between genetic risk and obesity

Genomics announces the appointment of David Thornton to the position of President, succeeding Professor Gil McVean, who will join the board as a non-executive Director.

Research by Genomics plc has identified that 8% of the adult population have the same risk of heart disease due to polygenic risk, as carriers of rare genetic mutations that cause familial hypercholesterolemia (FH).

The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.

Genomics plc has today announced that Mark Toms and Nick DeFilippo have joined its leadership team as Chief Medical Officer and Chief Commercial Officer, respectively. Both join the company’s executive leadership team.

Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.

Our research shows that those at high genetic risk of obesity will need personalised support to help them stay at, or return to, a healthy weight.

Genomics releases new research showing significant link between genetic risk and obesity

Genomics announces the appointment of David Thornton to the position of President, succeeding Professor Gil McVean, who will join the board as a non-executive Director.

Research by Genomics plc has identified that 8% of the adult population have the same risk of heart disease due to polygenic risk, as carriers of rare genetic mutations that cause familial hypercholesterolemia (FH).

The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.

Genomics plc has today announced that Mark Toms and Nick DeFilippo have joined its leadership team as Chief Medical Officer and Chief Commercial Officer, respectively. Both join the company’s executive leadership team.

Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.

Our research shows that those at high genetic risk of obesity will need personalised support to help them stay at, or return to, a healthy weight.

Genomics releases new research showing significant link between genetic risk and obesity

Genomics announces the appointment of David Thornton to the position of President, succeeding Professor Gil McVean, who will join the board as a non-executive Director.

Research by Genomics plc has identified that 8% of the adult population have the same risk of heart disease due to polygenic risk, as carriers of rare genetic mutations that cause familial hypercholesterolemia (FH).

The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.

Genomics plc has today announced that Mark Toms and Nick DeFilippo have joined its leadership team as Chief Medical Officer and Chief Commercial Officer, respectively. Both join the company’s executive leadership team.

Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.